Adicet raises $51 million series A

Adicet Bio Inc. (Menlo Park, Calif.) raised $51 million in a series A round led by OrbiMed. Other investors included Novartis Venture Fund and Pontifax. Adicet said it is developing preclinical universal immune cell therapies for cancer and other indications.

Also on Wednesday, Adicet acquired Applied Immune Technologies Ltd. (Haifa, Israel), a developer of T cell receptor-like antibodies that bind to disease-specific intracellular peptides that are presented on the cell surface. ...